Physiomics Share News (PYC)

IN BRIEF: Physiomics shares rise on Ankyra contract extension

Physiomics PLC - Oncology consultancy based in Oxford, England - Says it has been awarded a further contract by existing client Ankyra Therapeutics. The contract builds on work announced in March, and is expected to complete in the first quarter of 2023.

AIM WINNERS & LOSERS: Manolete swings to loss amid case troubles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Physiomics inks deal to work with Cancer Research UK

(Sharecast News) - Modelling and simulation-focussed consultancy Physiomics that it has signed an agreement to work with Cancer Research UK, it announced on Wednesday.

AIM WINNERS & LOSERS: Physiomics wins deal; DeepVerge eyes cash raise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Physiomics surges on contract win with Cancer Research UK

(Alliance News) - Physiomics PLC shares jumped on Wednesday after it signed an agreement to work with Cancer Research UK.

IN BRIEF: Physiomics wins third contract from Numab Therapeutics

Physiomics PLC - oncology consultancy based in Oxford, England - Wins third contract by an existing client, Numab Therapeutics. Says it will use its PKPD modelling capabilities to support the translation of pre-clinical to clinical data with a focus on dose selection. The project is expected to be completed between now and the end of 2022.

EARNINGS UPDATES: Crestchic raises outlook on record year-to-date

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Michelmersh Brick, Mattioli Woods on-track for growth

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Physiomics wins new contract for Virtual Tumour platform

Physiomics PLC - oncology consultancy based in Oxford, England - Wins new contract with Servier Group, an international pharmaceutical company with headquarters in France, to provide specialist mathematical modelling services using Virtual Tumour software platform. This will aid Servier in simulating the effects of immuno-oncology combinations in pre-clinical and clinical settings. The project will complete in the next seven to eight months, the company says. No financial details were provided.

Physiomics wins new contract with French pharma company

(Sharecast News) - Oncology drug developer Physiomics has been awarded a contract by new client, the Servier Group, an international pharmaceutical company based in France.

IN BRIEF: Physiomics confident for full-year, in talks for new client

Physiomics PLC - oncology consultancy based in Oxford, England - Pretax loss widens to GBP170,000 in six months that ended December 31 from GBP132,000 a year before, as revenue stays flat at GBP366,000 from GBP363,000. Notes has contracted revenue of GBP460,000 for the second of its financial year, which ends June 30, and is "well positioned to meet market expectations". Physiomics says it has a strong pipeline of products in advanced discussion, including with a potential new "large pharmaceutical client".

TRADING UPDATES: MediaZest virus hit; SpaceandPeople Network Rail deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

IN BRIEF: Physiomics chair steps down after 15 years; CEO adds role

Physiomics PLC - oncology consultancy based in Oxford, England - Non-Executive Chair Paul Harper steps down from board immediately, having served on the board since 2004 and as chair since 2007. Chief Executive Officer Jim Millen will take on the additional role of executive chair. Physiomics also will recruit one independent non-executive director "as soon as possible".

IN BRIEF: Physiomics shares up on continued DoseMeRx collaboration

Physiomics PLC - oncology consultancy based in Oxford - Confirms it will continue to collaborate with DoseMeRx, after Tabula Rasa Healthcare Inc announces it will sell DoseMeRx. The collaboration will explore further commercial opportunities in cancer field. Over 2021, Physiomics' personalised dosing application for docetaxel prostate cancer treatment was integrated into DoseMeRx platform, and was met with positive feedback.